van den Akker-van Marle ME - Search Results

1

Cost-effectiveness of cervical cancer screening: comparison of screening policies.

van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. van den Akker-van Marle ME, et al. J Natl Cancer Inst. 2002 Feb 6;94(3):193-204. doi: 10.1093/jnci/94.3.193. J Natl Cancer Inst. 2002. PMID: 11830609

2

Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness.

van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. van Ballegooijen M, et al. Br J Cancer. 1997;76(5):651-7. doi: 10.1038/bjc.1997.440. Br J Cancer. 1997. PMID: 9303366 Free PMC article.

3

Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round.

van den Akker-van Marle ME, Reep-van den Bergh CM, Boer R, Del Moral A, Ascunce N, de Koning HJ. van den Akker-van Marle ME, et al. Int J Cancer. 1997 Nov 14;73(4):464-9. doi: 10.1002/(sici)1097-0215(19971114)73:4<464::aid-ijc2>3.0.co;2-y. Int J Cancer. 1997. PMID: 9389557

4

Withdrawing low risk women from cervical screening programmes. Conclusions cannot yet be drawn.

van den Akker-van Marle ME, van Ballegooijen M, Boer R, van Oortmarssen GJ, Habbema JD. van den Akker-van Marle ME, et al. BMJ. 1999 Jul 3;319(7201):58. doi: 10.1136/bmj.319.7201.58. BMJ. 1999. PMID: 10390480 Free PMC article. No abstract available.

5

Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears.

Bos AB, van Ballegooijen M, van den Akker-van Marle ME, Hanselaar AG, van Oortmarssen GJ, Habbema JD. Bos AB, et al. Am J Clin Pathol. 2001 Jun;115(6):851-5. doi: 10.1309/RP84-MD34-8MFN-39UR. Am J Clin Pathol. 2001. PMID: 11392881

6

[Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996].

Bos AB, van Ballegooijen M, van den Akker-van Marle ME, Habbema JD. Bos AB, et al. Ned Tijdschr Geneeskd. 2002 Aug 24;146(34):1586-90. Ned Tijdschr Geneeskd. 2002. PMID: 12224483 Dutch.

7

Human papillomavirus testing for triage of women referred because of abnormal smears. a decision analysis considering outcomes and costs.

Meerding WJ, van Ballegooijen M, Burger MP, van den Akker-van Marle ME, Quint WG, Habbema JD. Meerding WJ, et al. J Clin Epidemiol. 2002 Oct;55(10):1025-32. doi: 10.1016/s0895-4356(02)00456-0. J Clin Epidemiol. 2002. PMID: 12464379

8

Low risk of cervical cancer during a long period after negative screening in the Netherlands.

van den Akker-van Marle ME, van Ballegooijen M, Habbema JD. van den Akker-van Marle ME, et al. Br J Cancer. 2003 Apr 7;88(7):1054-7. doi: 10.1038/sj.bjc.6600843. Br J Cancer. 2003. PMID: 12671704 Free PMC article.

9

Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy.

Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, Birnie E, Buijs-van der Woude T, Mali WP, de Koning HJ, Buskens E. Groenewoud JH, et al. Br J Cancer. 2004 Jan 26;90(2):383-92. doi: 10.1038/sj.bjc.6601520. Br J Cancer. 2004. PMID: 14735181 Free PMC article.

10

Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis.

van den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. van den Akker-van Marle ME, et al. Pediatrics. 2006 Sep;118(3):896-905. doi: 10.1542/peds.2005-2782. Pediatrics. 2006. PMID: 16950979

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters